Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exo… Read more
Sarepta Therapeutics Inc (SRPT) - Total Liabilities
Latest total liabilities as of September 2025: $2.17 Billion USD
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has total liabilities worth $2.17 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sarepta Therapeutics Inc - Total Liabilities Trend (1995–2024)
This chart illustrates how Sarepta Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sarepta Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sarepta Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Magnite Inc
NASDAQ:MGNI
|
USA | $2.11 Billion |
|
Xinhu Zhongbao Co Ltd
SHG:600208
|
China | CN¥54.99 Billion |
|
Meidensha Corporation
F:MW7
|
Germany | €183.01 Billion |
|
SSP Group PLC
PINK:SSPPF
|
USA | $3.15 Billion |
|
Megacable Holdings S. A. B. de C. V
PINK:MHSDF
|
USA | $37.96 Billion |
|
Southeast Asia Commercial JS Bank
VN:SSB
|
Vietnam | ₫356.07 Trillion |
|
Skyward Specialty Insurance Group, Inc. Common Stock
NASDAQ:SKWD
|
USA | $3.63 Billion |
Liability Composition Analysis (1995–2024)
This chart breaks down Sarepta Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sarepta Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sarepta Therapeutics Inc (1995–2024)
The table below shows the annual total liabilities of Sarepta Therapeutics Inc from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.44 Billion | +1.26% |
| 2023-12-31 | $2.41 Billion | -12.33% |
| 2022-12-31 | $2.74 Billion | +23.58% |
| 2021-12-31 | $2.22 Billion | -0.13% |
| 2020-12-31 | $2.22 Billion | +121.27% |
| 2019-12-31 | $1.00 Billion | +64.75% |
| 2018-12-31 | $609.80 Million | +17.55% |
| 2017-12-31 | $518.75 Million | +493.44% |
| 2016-12-31 | $87.41 Million | +4.77% |
| 2015-12-31 | $83.44 Million | +76.10% |
| 2014-12-31 | $47.38 Million | +6.77% |
| 2013-12-31 | $44.38 Million | -45.43% |
| 2012-12-31 | $81.31 Million | +248.22% |
| 2011-12-31 | $23.35 Million | -52.14% |
| 2010-12-31 | $48.79 Million | +34.06% |
| 2009-12-31 | $36.40 Million | +271.25% |
| 2008-12-31 | $9.80 Million | -20.01% |
| 2007-12-31 | $12.26 Million | +288.98% |
| 2006-12-31 | $3.15 Million | +14.66% |
| 2005-12-31 | $2.75 Million | +22.15% |
| 2004-12-31 | $2.25 Million | -40.03% |
| 2003-12-31 | $3.75 Million | -26.77% |
| 2002-12-31 | $5.12 Million | +56.11% |
| 2001-12-31 | $3.28 Million | +90.45% |
| 2000-12-31 | $1.72 Million | +72.28% |
| 1999-12-31 | $1.00 Million | -16.67% |
| 1998-12-31 | $1.20 Million | +140.00% |
| 1997-12-31 | $500.00K | -85.29% |
| 1996-12-31 | $3.40 Million | +1033.33% |
| 1995-12-31 | $300.00K | -- |